Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
CEO Valerie Vanhooren told Endpoints …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics consigue 74 millones para avanzar en sus fármacos contra el cáncer
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Alnylam, Inceptive ink AI deal potentially worth $2B
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced…
La compañía destinará buena parte de los recursos a los ensayos clínicos de su molécula estrella
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
